Combining RT With Immunotherapy and Chemotherapy in Metastatic Nasopharyngeal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 5, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2024

Conditions
Metastatic Nasopharyngeal Cancer
Interventions
RADIATION

Radiotherapy

Patients who had complete response or partial response after at least 3 cycles (no more than 6 cycles) of chemotherapy combined with immunotherapy receive local radiotherapy 21 days. For those non-CR oligo-metastatic disease or symptomatic lesion, SBRT or conventional RT delivered. Maintenance therapy of immunotherapy for 2 years.

Trial Locations (1)

Unknown

RECRUITING

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER